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Multifunctional nanosystems are one of the most promising therapeutic approaches in cancer 
treatment. The combination of the plasmonic effect with a superparamagnetic behavior results in 
materials with magnetic guidance, hyperthermia and controlled drug delivery capabilities in a single 
nanosystem [1]. Therefore, magnetic/plasmonic nanomaterials are promising in cancer therapy for 
simultaneous chemotherapy and phototherapy, as they can act both as magnetic and photothermal 
agents, allowing magnetic guidance, local temperature increase and triggered drug release.   
 
In this work, MnFe2O4/Au core/shell nanoparticles (NPs) and MnFe2O4 NPs decorated with Au NPs 
were synthesized and the structural, spectroscopic and magnetic properties evaluated. The prepared 
NPs were covered with a lipid bilayer, forming solid magnetoliposomes (SMLs) [2,3]. The heating 
capabilities of the nanosystems were assessed through the fluorescence quenching of Nile Red 
(incorporated in the lipid bilayer of the SMLs) under irradiation [4]. Two novel antitumor thienopyridine 
derivatives (tricyclic lactones 1 and 2, figure 1) were encapsulated in the lipid bilayer of the SMLs and 
the growth inhibitory activity in human tumour cell line NCI-H460 (non-small cell lung cancer), was 
evaluated in the presence and absence of a light source. SMLs were also tested in non-tumor cells, 
under irradiation, for comparison. Low inhibitory concentrations of 0.11 µM and 0.12 µM were 
observed for SMLs based on MnFe2O4/Au core/shell NPs loaded with compound 1 and 2, 
respectively, pointing these nanosystems as promising therapeutic agents in future applications of 
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Figure 1: Structure of the tricyclic lactones derivatives of thienopyridine. 
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